文献速递药物不良反应与药物警戒

WHO-ISoP药物警戒课程:2026年更新版

The WHO-ISoP Pharmacovigilance Curriculum: 2026 Update.
PubMed 文献 · Drug Saf · 2026-09-20

本文介绍世界卫生组织(WHO)与国际药物警戒学会(ISoP)联合开发的药物警戒课程,系对2014年课程的重大更新。课程保留三级层次结构,章节由15章增至26章,实践任务由40项增至125项,参考文献由260条增至469条,涵盖先进疗法、全球卫生紧急事件、抗菌药物耐药、数字健康、人工智能等新主题,旨在为各类机构开发情境化培训提供参考框架。

要点

  • 课程为WHO与ISoP联合开发,保留三级层次结构,章节从15章增至26章。
  • 新增先进疗法、人工智能、真实世界证据、医疗器械安全等当代主题。
  • 实践任务由40项增至125项,参考文献由260条增至469条,以电子补充材料提供。

核心结论

  • 该课程提供当代药物警戒的全面结构化清单,可作为讲师和机构开发情境化培训的参考,反映WHO与ISoP加强药物警戒教育的共同承诺。

研究设计与样本

  • 由WHO与ISoP联合开发,通过涉及82名来自不同地区和专业背景贡献者的国际合作完成,系2014年课程的重大更新。

主要发现

  • 课程保留原有三级层次结构,每章分为四节,每节分为五或六个小节。
  • 章节数由15章增至26章,实践任务由40项增至125项,参考文献由260条增至469条。
  • 新增主题涵盖先进疗法、全球卫生紧急事件、抗菌药物耐药、数字健康、人工智能、真实世界证据、医疗器械安全、药物环境影响、风险沟通和患者参与。

关键数值与推荐

  • 课程支持开发入门、进阶、综合或专题性药物警戒教育项目,不规定单一标准化课程。
  • 结构和内容允许根据环境、学习者角色与先验知识、本地优先事项、可用时间和资源进行调整。

临床怎么用

  • 临床药学智能体医生可依据该课程框架设计或选择适合本机构的情境化药物警戒培训内容。
  • 可参考课程中的实践任务和参考文献(电子补充材料)组织教学与能力评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This article presents a pharmacovigilance (PV) curriculum which was jointly developed by the World Health Organization (WHO) and the International Society of Pharmacovigilance (ISoP). It is an expanded update of a PV curriculum which WHO and ISoP developed in 2014 and responds to major scientific, technological, regulatory, social and public health developments that have reshaped PV over the last 12 years. Topics such as advanced therapies, global health emergencies, antimicrobial resistance, digital health, artificial intelligence, real-world evidence, medical device safety, the environmental impact of medicines, risk communication and patient engagement are addressed. The curriculum was developed through an international collaboration involving 82 contributors from different regions and professional backgrounds. The original three-level hierarchical structure was retained, with each chapter divided into four sections and each section into five or six subsections. The number of chapters increased from 15 to 26, the number of practical tasks from 40 to 125 and the number of references from 260 to 469. Practical tasks and references are provided as Electronic Supplementary Materials. The curriculum provides a comprehensive and structured inventory of contemporary PV and thus represents a reference that lecturers and institutions can use to develop context-specific training programmes. Its structure provides conceptual clarity while allowing adaptation to different settings, learners' roles and prior knowledge, local priorities, available time and resources. It is not intended to prescribe a single standardised course. Instead, it supports the development of introductory, advanced, comprehensive or topic-specific PV education programmes. The update reflects a shared commitment of the WHO and the ISoP to strengthening PV education and capacity across regulatory, academic, healthcare, public health and industrial settings in accordance with the recommendation of the 2026 World Health Assembly to strengthen PV.

来源:Drug Saf,查看原文。版权归原作者所有。

引用

  1. Beckmann J, Tuccori M, Bahri P, et al. The WHO-ISoP Pharmacovigilance Curriculum: 2026 Update. Drug Saf. 2026. PMID: 42763845. doi:10.1007/s40264-026-01717-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。